• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific touts real-world outcomes for Watchman FLX LAAC device

Boston Scientific touts real-world outcomes for Watchman FLX LAAC device

February 28, 2022 By Sean Whooley

Boston Scientific Watchman FLX
[Image from Boston Scientific]
Boston Scientific (NYSE:BSX) today announced positive real-world outcomes with its Watchman FLX left atrial appendage closure (LAAC) device.

Marlborough, Massachusetts–based Boston Scientific posted data from the Surpass real-world analysis at the Cardiovascular Research Technologies (CRT) 2022 meeting.

Surpass included data from more than 16,000 patients with non-valvular atrial fibrillation (AFib) within the National Cardiovascular Data Registry (NCDR) Left Atrial Appendage Occlusion (LAAO) Registry, according to a news release. The data demonstrated only a 0.37% rate of major adverse events at seven days following a Watchman FLX implant or the time of hospital discharge (whichever came later).

Other key outcomes recorded at a 45-day follow-up point following Watchman FLX implant included a 0.51% rate of pericardial effusion requiring either surgical or percutaneous intervention, with 0.03% of patients requiring cardiac surgery, the company said.

Boston Scientific said the key safety endpoint was defined as a composite of all-cause death, ischemic stroke, systemic embolism or device/procedure-related events requiring open cardiac surgery or major endovascular intervention.

Watchman FLX was successfully implanted in 97.6% of patients, with low rates of ischemic stroke (0.28%) and device embolization (0.03%) at 45 days. The Surpass analysis remains ongoing and will collect outcomes through at least two years post-implant on all patients in the registry treated with Watchman FLX between August 2020 and August 2022. The key effectiveness endpoint of ischemic stroke or systemic embolism will be evaluated after 24 months.

“The strong safety and efficacy profile of the Watchman FLX device demonstrated in the Surpass analysis reinforces many of the safety and effectiveness results seen in the pivotal Pinnacle FLX trial, while representing a high-risk, real-world patient population and wide variety of patient anatomies,” Boston Scientific Global CMO Dr. Ian Meredith said in the release. “We look forward to further analyses from this large, representative study of patients with NVAF treated by physicians with a broad range of implanting experience.”

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Featured, News Well, Replacement Heart Valves, Structural Heart Tagged With: Boston Scientific

More recent news

  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year
  • Axoft makes Fleuron BCI material available for purchase, inks license deal with Stanford
  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy